Program
givinostat hydrochloride
Also written as “Givinostat Hydrochloride” and “Givinostat Hydrochloride - Cohort 2”.
Its studies are mostly in Muscular Dystrophy, Duchenne, led by Italfarmaco.
Furthest: phase 2, since Dec 11, 20241 company-led study, 1 open or runningNext primary completion: Dec 2029 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Italfarmaco | 11 open or running | phase 2since Dec 11, 2024 | Dec 11, 2024 | Dec 2029phase 2 · NCT06769633 |
Also a collaborator on its studies: Fortrea.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 11, 2024First study: phase 2 study in Muscular Dystrophy, DuchenneFirst studyNCT06769633 · 18 planned · Belgium, Italy, Netherlands and more
Ahead
- Dec 2029Primary completion: phase 2 study in Muscular Dystrophy, DuchenneNCT06769633
TargetBeta
“Histone deacetylase inhibitor”ChEMBL 37, by rule
Other programs on the same 11 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| givinostatrule | Italfarmaco | phase 3 | 23 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06769633Muscular Dystrophy, Duchenne · Belgium, Italy, Netherlands and more | 2 | Recruiting | Dec 2029 | 18 |
How it is read
Names in the registry
- “Givinostat Hydrochloride”, 1 entry
- “Givinostat Hydrochloride - Cohort 2”, 1 entry
Conditions, from the studies’ own filings
- Muscular Dystrophy, Duchenne, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.